Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'
July 26, 2017 10:53 AM EDTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $328.00 (from $317.00) while maintaining a Market Perform rating, following the company's second quarter earnings announcement.
Analyst M. Ian Somaiya notes the company delivered second quarter earnings per share and revenues above consensus... More
Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q
July 26, 2017 8:44 AM EDTUBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.
Despite a strong 2Q print, the mid-to-long term outlook... More
Biogen (BIIB) PT Raised to $319 at Deutsche Bank
July 26, 2017 6:24 AM EDTDeutsche Bank raised its price target on Biogen (NASDAQ: BIIB) to $319.00 (from $315.00) while maintaining a Buy rating amid solid Q2 results and strategic review.
Analyst Andrew Peters commented, "The outperformance, driven primarily by strength in the MS franchise, as well as by continued... More
